

1 Household transmission of SARS-CoV-2 during the Omicron wave in 2 Shanghai, China : a case-ascertained study

3 Zhongqiu Wei^{1#}, Wenjie Ma^{1#}, Zhonglin Wang^{1#}, Jingjing Li¹, Xiaoming Fu¹, Hailing Chang¹,
4 Yue Qiu¹, He Tian¹, Yanling Ge¹, Yanfeng Zhu¹, Aimei Xia¹, Qianhui Wu², Gongbao Liu³,
5 Xiaowen Zhai⁴, Xiaobo Zhang⁵, Yan Wang^{2*}, Mei Zeng^{1,6*}

6 Author Affiliations:

- 7 1. Department of Infectious Disease, Children's Hospital of Fudan University, Shanghai,
8 China
- 9 2. School of Public Health, Fudan University, Key Laboratory of Public Health Safety,
10 Ministry of Education, Shanghai, China
- 11 3. Department of Medicine, Children's Hospital of Fudan University, Shanghai, China
- 12 4. Department of Hematology and Oncology, Children's Hospital of Fudan University,
13 Shanghai, China
- 14 5. Department of Respiratory Medicine, Children's Hospital of Fudan University, Shanghai,
15 China
- 16 6. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai,
17 China.

18 [#] Zhongqiu Wei, Wenjie Ma and Zhonglin Wang contributed equally to this work.

19 ^{*} Yan Wang and Mei Zeng Shared corresponding author.

20 Abstract

21 **Background:** Since late 2021, the highly transmissible SARS-CoV-2 Omicron variant has
22 driven a new surge of infections across the world. We used a case-ascertained study to
23 determine the features of household transmission of SARS-CoV-2 Omicron variant in

24 Shanghai, China.

25 **Methods:** We collected detailed information on 323 pediatric cases and their 951 household
 26 members in April 2022 during the Omicron outbreak. All household members received
 27 consecutively intensive RT-PCR testing for SARS-CoV-2 and routine symptom monitoring
 28 within 14 days after exposure to a confirmed case. We described the characteristics of study
 29 participants and estimated the transmission parameters. Both secondary infection attack rates
 30 (SAR_I) and secondary clinical attack rates (SAR_C) among adult household contacts were
 31 computed, through which the transmission heterogeneities in infectivity and susceptibility
 32 were characterized and the vaccine effectiveness were estimated.

33 **Results:** We estimated the mean incubation period of SARS-CoV-2 Omicron variant to be 4.6
 34 (median: 4.4, IQR: 3.1-6.0) days and the mean serial interval to be 3.9 (median: 4.0, IQR:
 35 1.4-6.5) days. The overall SAR_I and SAR_C among adult household contacts were 77.11% (95%
 36 confidence interval [CI]: 73.58%-80.63%) and 67.03% (63.09%-70.98%). We found higher
 37 household susceptibility in females, while infectivity was not significantly different in
 38 primary cases by age, sex, vaccination status and clinical severity. The estimated VEs of full
 39 vaccination was 14.8% (95% CI: 5.8%-22.9%) against Omicron infection and 21.5% (95%
 40 CI: 10.4%-31.2%) against symptomatic disease. The booster vaccination was 18.9% (95% CI:
 41 9.0%-27.7%) and 24.3% (95% CI: 12.3%-34.7%) effective against infection and
 42 symptomatic disease, respectively.

43 **Conclusions:** We found high household transmission during the Omicron wave in Shanghai
 44 due to asymptomatic and pre-symptomatic transmission in the context of city-wide lockdown,
 45 indicating the importance of early detection and timely isolation of SARS-CoV-2 infections

46 and quarantine of close contacts. Marginal effectiveness of inactivated vaccines against
47 Omicron infection poses great challenge for prevention and control of the SARS-CoV-2
48 Omicron variant.

49 **Keywords:** SARS-CoV-2, Omicron variant, household transmission, vaccine effectiveness.

50

51 **Background**

52 The COVID-19 pandemic caused by SARS-CoV-2 has resulted in unprecedented global
53 health crisis and more than six million deaths worldwide since December 2019 [1]. Despite
54 the increasing natural immunity and vaccine-induced immunity are common in population,
55 the newly emerged Omicron variant, with increased transmissibility and immune escape
56 properties, has rapidly replaced previous strains and driven a new surge of SARS-CoV-2
57 infections across the world [2, 3]. China maintained local containment through effective
58 border controls and non-pharmaceutical interventions (NPIs) since 2020 and has successfully
59 coped with several importation-linked local outbreaks of SARS-CoV-2 variants [4]. In the
60 meantime, Chinese government spared no efforts to promote countrywide mass COVID-19
61 vaccination roll-out among adults since April 2021 and among children aged 3-17 years since
62 July 2021 [5,6]. Nevertheless, following the first cluster of Omicron infections detected in
63 late February, 2022, a local epidemic wave caused by Omicron BA.2 sub-lineage hit
64 Shanghai, one of the largest metropolitans with a population of nearly 25 million in China,
65 with widespread community transmission occurred in late March and peaked in April, despite
66 the implementation of mass vaccination and city-wide lockdown [7]. As of May 31, 2022,

67 when the lockdown was lifted, over 0.6 million confirmed cases including 588 deaths were
68 reported in Shanghai [8].

69 Transmission dynamics of SARS-CoV-2 may potentially evolve over time and vary by
70 settings and with intervention measures. Households are important transmission venues for
71 SARS-CoV-2 [9-11]. A full understanding of the household transmission patterns of
72 SARS-CoV-2 Omicron variant is crucial to plan and adjust the public health responses and
73 target intervention in face of the current challenge of Omicron epidemics. Recently, a few
74 studies from Danish, Norway and the US have reported higher household secondary attack
75 rates (25.1%~52.7%) for Omicron variant than for Delta variant [12-16]. However, accurately
76 determining the household transmission dynamics regardless of symptoms remains
77 challenging, as most studies were based on the analysis of symptom-based screening data,
78 with asymptomatic infections and mild non-medically consulted infections underreported.
79 This challenge can be addressed by studies of close contacts with routine SARS-CoV-2
80 testing regardless of symptoms to detect asymptomatic and mildly symptomatic cases. As
81 household contacts of SARS-CoV-2-positive cases are likely to be highly exposed to the case
82 and are known to be at high-risk of infection, they are an ideal group shedding lights on
83 SARS-CoV-2 transmission dynamics [17].

84 Here, we conducted a case-ascertained study to determine the features of household
85 transmission of SARS-CoV-2 Omicron variant in Shanghai, China. In particular, we
86 estimated the distribution of key time-to-event intervals, quantified the household
87 transmission risk and explored the transmission heterogeneities in infectivity and

susceptibility. In the meantime, we also assessed the vaccine effectiveness of inactivated COVID-19 vaccines against Omicron infection and symptomatic disease.

Methods

Cases and household contacts

A confirmed case is defined as a person with PCR-confirmed SARS-CoV-2 infection, irrespective of clinical signs and symptoms, and further classified as asymptomatic, mild, moderate (non-severe pneumonia), severe and critical case based on both national and World Health Organization (WHO) guidance [18,19]. Pneumonia was diagnosed based on either radiological evidence or typical clinical signs (fever and or cough accompanying with one of the following signs: moist rales, difficulty in breathing, fast breathing, chest indrawing).

A household is defined as two or more people living in the same residence. A household contact is defined as any person who has resided in the same household with a confirmed case for the period from 2 days before to 14 days after the date of symptom onset or laboratory confirmation. As a part of public health monitoring, consecutively intensive RT-PCR testing and routine symptom monitoring within 14 days after exposure to a confirmed case are required for all household contacts every day or every other day [20].

The primary case(s) of a household was defined as confirmed case(s) with a history of community exposure (i.e., exposed to SARS-CoV-2 contaminated environment or contact with a confirmed case in the community). For a household without determined source of infection, we defined the primary case(s) as the first individual(s) who was tested positive

with RT-PCR or developed symptoms. Other household members with positive RT-PCR results were defined as secondary cases.

Study design and participants

This case-ascertained study was conducted in April 2022 at the Children's Hospital of Fudan University, a designated hospital for management of pediatric COVID-19 cases in Shanghai. During the study period when a large number of pediatric cases of SARS-CoV-2 infection were detected through mass screening, the majority of pediatric cases younger than 5 years old with febrile symptom and all pediatric cases with suspected pneumonia or comorbidities requiring special medical attention were referred to the designated children's hospitals, while most asymptomatic and milder pediatric cases were transferred to designated isolation facilities for medical observation. We enrolled a total of 335 pediatric cases infected with SARS-CoV-2 Omicron variant who were referred to the Children's Hospital of Fudan University during April 4 to April 27(Fig. 1). All cases were PCR-confirmed before hospitalization. The confirmed cases are discharged from isolation if the cycle threshold (Ct) value ≥ 35 for the viral nucleic acid on RT-PCR test [18].

We further enrolled all household members of the hospitalized children and followed up household cases until one week after discharge. The households were excluded from the study if any of the household members were reluctant to provide the complete information or refused to telephone follow-up. (Fig. 1).

Data collection

All hospitalized children had at least one household member living together. The household information of each hospitalized case was collected according to case management requirement, including demographics, exposures, vaccination status and symptoms. Clinical data of hospitalized children was extracted from the electronic medical records. Other detailed data on hospitalized children and their household contacts were obtained through face-to-face interview to the accompanying parents using a standard questionnaire (Table S1) during the hospital stay and through the routine telephone follow-up one week after discharge.

Statistical analysis

We estimated the incubation period (i.e., the period of time from an exposure resulting in SARS-CoV-2 infection to symptom onset) by analyzing cases with clear exposure history. When multiple or sustained exposure was reported, the time interval between the first and last recorded dates of exposure was considered to account for the uncertainty of infection time. We also estimated the serial interval (i.e., the time interval between the onset of symptoms in a primary case and his/her secondary cases). For a secondary case contacts with multiple infections, we randomly selected one as his/her primary case and simulated 100 times to account for potential uncertainties. We fitted three parametric distributions (Weibull, gamma and lognormal) to time-to-event data and selected the best fit based on the minimum Akaike information criterion. The distributions of serial interval were fitted with a shift parameter allowing negative values.

For the household transmission study, we excluded the households with two or more primary cases and the households without determined primary cases from the analysis to avoid potential bias (Fig. 1), as it is possible that a secondary case may be misclassified as a co-primary case. The secondary infection attack rate (SAR_I) was defined as the number of PCR-confirmed cases detected regardless of symptom among all household contacts of the primary case [17]. The secondary clinical attack rate (SAR_C) was defined as the number of symptomatic cases detected among all household contacts of the primary case [17]. In this study, there was a potential bias in the estimates of SAR_I and SAR_C among children household contacts due to the study design that the enrolled households were selected from the families of the confirmed hospitalized pediatric cases. Therefore, we estimated the SAR_I and SAR_C among adult household contacts to assess the heterogeneities in infectivity and susceptibility. Specifically, the heterogeneities in susceptibility were estimated by the characteristics (e.g., sex and vaccination status) of adult household contacts. The heterogeneities in infectivity were measured by the characteristics (e.g., age, sex, symptom profile and vaccination status) of primary cases (including children and adults).

Comparison between groups was performed using chi-square test. A difference with $P < 0.05$ at two-side was considered to be statistically significant. We estimated the vaccine effectiveness against Omicron infection (VE_I) and against clinical symptoms (VE_C) based on the estimates of SAR_I and SAR_C among adult household contacts with different vaccination status. Specifically, the estimates of VE_I were obtained from $VE_{I,v} = 1 - (SAR_{I,v} / SAR_{I,u})$, where $v = 1, 2, 3$, donates the partially, fully and booster vaccinated groups among the adult household contacts, respectively. $SAR_{I,v}$ donates the secondary infection rate of

each vaccinated group and $SAR_{I,u}$ denotes that of the unvaccinated group. Similarly, the estimates of VE_C were obtained from $VE_{C,v} = 1 - (SAR_{C,v}/SAR_{C,u})$, where $SAR_{C,v}$ denotes the secondary clinical attack rate of each vaccinated group and $SAR_{C,u}$ denotes that of the unvaccinated group. Statistical analysis was performed using the R software, version 4.0.2; the data were stored and maintained using Microsoft Office Excel 2019.

Results

A total of 1274 participants from 297 households, including 323 hospitalized children and 951 household contacts, were finally recruited to the study (Fig. 1). Their epidemiological and clinical characteristics were described in Table S2 and Fig. S1. All household cases in this study were non-severe or asymptomatic, except a 7-year-old child, who was critically ill.

We analyzed the period of time from exposure resulting in SARS-CoV-2 infection to disease onset for the 52 symptomatic cases with clear exposure history. We estimated a mean incubation period of 4.6 (median: 4.4, IQR: 3.1-6.0) days, with a standard deviation (sd) of 2.1 days and the 95th percentile of the distribution at 8.3 days (Fig. 2A). The incubation period was well approximated by a Weibull distribution (Table S3). We estimated the time of symptom onset between the 234 transmission pairs. The serial interval followed a best fitted Weibull distribution with an estimated mean of 3.9 (median: 4.0, IQR 1.4-6.5) days and a standard deviation of 3.7 days (Fig. 2B, Table S4).

For household transmission study, we excluded 43 households with two or more primary cases, 15 households without primary cases determined and 3 households without adult

household contacts (see Method section for details). We finally included 236 primary cases and their 546 adult household contacts for analysis (Fig. 1). The characteristics of the 236 primary cases and their 546 adult household contacts were described in Table 1. Among the 236 household primary cases, 169 (71.61%) were adults and 134 (56.78%) were females. Only 89 (37.71%) of the primary cases reported a clear history of community SARS-CoV-2 exposure, indicating most of the households without a determined source of infection. We found 37.71% of the primary cases were unvaccinated, 2.97%, 35.59% and 23.73% of the primary cases received partial, full and booster vaccination, respectively. Most primary cases (89.83%) were symptomatic. Among the 546 adult household contacts, 421 secondary cases were identified and 366 (86.94%) developed symptoms. The overall SAR_I and SAR_C among adult household contacts were 77.11% (95% CI: 73.58%-80.63%) and 67.03% (95% CI: 63.09%-70.98%), respectively. We found the infectivity was not significantly different in primary cases with different age, sex, vaccination status and symptom profile ($P>0.05$, Table 2). For the transmission heterogeneities in susceptibility, we found a higher proportion of females (59.86% vs 38.4%) and a lower proportion of vaccinated individuals (76.72% vs 89.9%) in secondary cases than in uninfected household contacts (Table 1). Accordingly, we found higher susceptibility to SARS-CoV-2 Omicron infection in females ($SAR_I=84\%$) within household than in males ($SAR_I=68.7\%$, $p<0.001$). Similar conclusion was reached when the susceptibility was measured by SAR_C (74% for females and 58.54% for males, $p<0.001$). Unvaccinated adults were associated with the highest risk of household infection ($SAR_I=88.29\%$) and symptomatic infection ($SAR_C=81.08\%$), while SAR_I could be reduced to 84%, 75.21% and 71.59% ($P=0.007$), and SAR_C could be reduced to 76%, 63.68% and 61.36%

($p=0.002$), through partial, full and booster vaccination, respectively (Table 3).

Full vaccination was 14.8% (95% CI: 5.8%-22.9%) and 21.5% (95% CI: 10.4%-31.2%) effective against Omicron infection and symptomatic disease. The estimated VE of booster vaccination was 18.9% (95% CI: 9.0%-27.7%) against Omicron infection and 24.3% (95% CI: 12.3%-34.7%) against symptomatic disease. By contrast, partial vaccination has no significant effect on preventing Omicron infection (4.9%, 95%CI: -14.4%-20.8%) and symptomatic disease (6.3%, 95%CI: -18.9%-26.1%) (Table 4).

Discussion

This study of household transmission patterns is based on a well-designed case-ascertained study during the Omicron wave in Shanghai, China, with detailed household investigations and consecutively intensive RT-PCR testing. Our results showed high risk of household transmission due to the transmission from pre-symptomatic and asymptomatic infections, despite the implementation of city-wide lockdown and centralized isolation/quarantine of cases and close contacts in hospitals or designated facilities. We observed no significant difference in transmissibility between symptomatic and asymptomatic individuals and between age, sex and vaccination groups, while susceptibility to Omicron infection among female household contacts was higher than males. Our findings also implied marginal effectiveness of inactivated vaccines against Omicron infection and symptomatic diseases, although inactivated vaccines may show high effectiveness against severe outcomes [18-20].

In this study, detailed information on exposures and symptoms of the study participants was

collected through in-depth household investigations, allowing us to provide robust estimation of several key time-to-event distributions. We observed a mean incubation period of 4.6 ± 2.1 days for Omicron variant, slightly longer than prior estimates for Omicron (3.0-3.6 days) [21-25] while shorter than that of the ancestral strain (6.3 days)[26]. The 95th percentile of the incubation period distribution was at 8.3 days, suggesting the feasibility of a shorter quarantine period for close contacts or population at risk. Additionally, studies from Spanish, Netherlands, South Korea, Belgium and the US showed shorter serial intervals for Omicron, with the mean estimates ranging from 2.75-4.8 days [12,25,27,28,29,30,31]. In agreement with prior findings, we observed a mean serial interval of 3.9 ± 3.7 days, falling within this interval. Shortened serial interval suggested increased transmissibility and growth advantage of Omicron variant, making timely contact tracing more challenging [32].

Omicron infection resulted in high attack rates among household contacts in this investigation. We estimated the overall SAR_I among adult household contacts to be 77.11%, around 2.5-6 times higher than previous estimates (13.2%~31.6%) in Wuhan, Zhejiang, Shenzhen, Guangzhou and Beijing during the first COVID-19 wave in China when the national lockdown was implemented [10, 33-36], consistent with prior studies indicating increased transmissibility of Omicron to preexisting variants [13,15, 37]. The overall estimates of SAR_C among adult household contacts in our study were 67.03%, higher than that reported in the US (52.7%), Danish (31%) and Norway (25.1%) [15-17]. This may be partially explained by the longer duration and higher frequency of contacts between household members during the lockdown period, as well as the circulation of more transmissible Omicron BA.2

sublineage in Shanghai [16]. More particularly, our investigation captured all potential household secondary infections as centralized isolation was required for all household contacts for medical observation and intensive RT-PCR testing regardless of symptom. Besides, despite strict NPIs were implemented in Shanghai (e.g., city-wide lockdown, stay-at-home order, mass testing and isolation/quarantine of all SARS-CoV-2 infections and close contacts), our study showed that silent transmission from pre-symptomatic and asymptomatic infections largely reduced the impact of interventions on stopping the household transmission, stressing the importance of early detection and timely isolation of the confirmed cases and quarantine of their contacts.

During the Omicron wave, substantial increase in pediatric cases of COVID-19 was reported in the US [38]. However, the role of children in Omicron transmission has yet to be fully understood. We observed similar high infectivity in pediatric cases (aged 0-17 years) and in adults (aged 18+ years), indicating that children played an equal role in Omicron transmission in household as adults. We found females were more susceptible to Omicron infection in household than males, in line with the finding reported in an early study from Wuhan [10]. Part explanation was that females are more likely to be the caregivers for the sick cases in households. Our finding also demonstrated the similar high-level transmission rate from symptomatic and asymptomatic primary cases, which implies that symptom-based surveillance is insufficient to prevent and control of COVID-19 epidemic, posing great challenge for prevention and control of Omicron transmission. Of particular note, we observed significantly higher susceptibility to Omicron infection for unvaccinated household

274 contacts, consistent with the findings reported in the latest studies from the US, Danish and
 275 Norway [37,12-15]. The estimated VEs against Omicron infection and symptomatic disease
 276 was 14.8% and 21.5% for fully vaccination, and 18.9% and 24.3% for booster vaccination.
 277 An update meta-analysis based on 4 household transmission studies from Danish, Norway
 278 and the US reported that the effectiveness of mRNA vaccines for fully vaccinated contacts
 279 was 18.1% [37], which is similar to our findings. The marginal VEs against Omicron
 280 infection and mild disease suggest significant immune escape of Omicron variant to
 281 vaccine-induced antibody protection and waning vaccine immunity over time [39, 40].
 282 However, the role of the current COVID-19 vaccines remains valuable in minimizing the
 283 direct disease burden of SARS-CoV-2 Omicron variant because VE estimates against the
 284 Omicron variant remain higher for severe disease in the majority of studies [40]. For severe
 285 disease caused by Omicron variant, VE of the primary series showed little decline over six
 286 months and the first booster dose vaccination improved VE ($\geq 70\%$) following three to six
 287 months from a booster dose [40].

288 Household transmission patterns are somewhat heterogeneous across studies. The accuracy of
 289 the results may be affected by a high degree of methodologic heterogeneity with respect to
 290 method and frequency of testing for diagnosis of contacts, isolation of cases and duration of
 291 follow-up. A major strength of this study is that we captured all secondary symptomatic and
 292 asymptomatic infections of the recruited households as all household members received
 293 consecutive RT-PCR testing for SARS-CoV-2 after a primary household case was identified.
 294 The estimation of VE is more objective because exposure risk and contact pattern of

household individuals are equal and homogeneous relative to the population-based observational study. However, our study is not without limitations. First, despite in-depth household investigation and follow-up of each case, we could not always reconstruct the entire transmission chain and fully avoid recall bias in individual records. We tried to collect information on source of exposures for each household to avoid potential bias, but there are still some households without determined source of infection. The primary cases of these households were defined as the first household members with positive RT-PCR testing results or the sign of COVID-19 symptoms, which may misclassify the primary and secondary cases of a households. Second, due to the study design (i.e., the study households were selected from those of the confirmed pediatric cases), we can only estimate the transmission risk among adult household contacts, the susceptibility of household children cannot be assessed. Third, we did not collect specific age of household contacts, only classified them as children (i.e., 0-17 years) and adults (i.e., 18+ years). Further investigations with detailed age information could help provide age-specific infectivity and susceptibility of Omicron variant. Multivariate analysis adjusted for age, sex and other related factor should be conducted to estimate the vaccine effectiveness.

Conclusions

In conclusion, high household transmission during the Omicron wave in Shanghai indicates the importance of early detection and timely isolation of SARS-CoV-2 infections. Marginal effectiveness of inactivated vaccines against Omicron infection poses great challenge for prevention and control of the SARS-CoV-2 Omicron variant, implying the necessity of

316 optimizing vaccine strategies.

317

318 **Abbreviations**

319 SAR_I: Secondary infection attack rate; SAR_C: Secondary clinical attack rate; CI: Confidence
320 interval; NPIs: Nonpharmaceutical interventions; WHO: World Health Organization; Ct:
321 Cycle threshold; VE: Vaccine effectiveness; VE_I: VE against Omicron infection; VE_C: VE
322 against clinical symptoms; sd: standard deviation

323 **Acknowledgments**

324 We thank Professor Hongjie Yu for his critical comments on the manuscript. We also thank
325 all participating children, parents and grandparents for their collaboration with investigation.

326 **Funding**

327 This study was supported by the Science and Technology Commission of Shanghai
328 Municipality [grant number 20JC141020002], Three-Year Action Plan for Strengthening the
329 Construction of Public Health System in Shanghai (2020-2022) [grant number GWV-3.2] and
330 the Key Development Program of Children's Hospital of Fudan University [grant number
331 EK2022ZX05].

332

333 **Ethics approval and consent to participate**

334 Data collection and analysis during the field investigation was a part of public health
335 outbreak investigation. This study was approved by the hospital institutional ethical review
336 board and participant's informed consent was waived.

337 **Authors' contributions**

338 MZ conceived, design and supervised this study. YW designed this study and did statistical
339 analyses. ZW, ZW, JL, XF, HC, YQ, HT, YG, YZ, and AX collected the data and followed up
340 children and their household members. WM and JL pooled the data. YW, WM and ZW did
341 statistical analyses under the supervision of MZ. MZ, YW, ZW, ZW and WM wrote the
342 manuscript, made tables and figures. ZW, ZW and WM edited the submitted manuscript. GL,
343 XZ and XZ provide advice on management of patients and implementation of the study. All
344 authors approved the manuscript for publication.

345 **Declarations**

346 **Availability of data and materials**

347 All data generated or analyzed during this study are included in this published article and its
348 supplementary information files.

349 **Competing interests**

350 The authors declare that they have no competing interest.

351

352 **Reference**

- 353 1. World Health Organization. WHO Health Emergency Dashboard. Available at:
354 <https://covid19.who.int/>. Accessed 6 July 2022.
- 355 2. World Health Organization. Weekly epidemiological update on COVID-19 - 1 March
356 2022. Available from:

- 357 <https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19--->
358 1-march-2022. Accessed 31 March 2022.
- 359 3. World Health Organization. Enhancing response to Omicron SARS-CoV-2 variant:
360 Technical brief and priority actions for Member States. Available at:
361 [https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-\(b.1.1.529\)-te](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states)
362 [chnical-brief-and-priority-actions-for-member-states](https://www.who.int/publications/m/item/enhancing-readiness-for-omicron-(b.1.1.529)-technical-brief-and-priority-actions-for-member-states). Accessed 22 April 2022.
- 363 4. Liu J, Liu M, Liang W. The Dynamic COVID-Zero Strategy in China. China CDC Wkly.
364 2022; 4(4): 74-5.
- 365 5. National Health Commission of The People's Republic of China. Technical guideline for
366 COVID-19 vaccination (the first version). 29 March 2021. Available from:
367 <http://www.nhc.gov.cn/jkj/s3582/202103/c2febfd04fc5498f916b1be080905771.shtml>.
368 Accessed 22 April 2022.
- 369 6. The Joint Prevention and Control Mechanism of the State Council. Emergence use of
370 COVID-19 vaccines for children 3-17 years. 12 June 2021.
371 http://www.gov.cn/xinwen/2021-06/12/content_5617310.htm. Accessed 22 April 2022.
- 372 7. Xian L, Lin J, Yu S, et al. Analysis of epidemiological characteristics of SARS-CoV-2
373 outbreak in the Spring of 2022 in Shanghai. Shanghai J Prevent Med 2022;
374 34(4):294-299.
- 375 8. Shanghai Municipal Health Commission. COVID-19 daily notification. Available at:
376 <https://wsjkw.sh.gov.cn/xwfb/20220601/7aa162269af54a4dabae745722f46c3a.html>. 1
377 June 2022.
- 378 9. World Health Organization. Report of the WHO-China joint mission on coronavirus
379 disease 2019 (COVID-19). 2020. Available at:
380 [https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronav](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19))
381 [irus-disease-2019-\(covid-19\)](https://www.who.int/publications/i/item/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)). Accessed 24 May 2022.

- 382 10. Li F, Li Y, Liu M, et al. Household transmission of SARS-CoV-2 and risk factors for
383 susceptibility and infectivity in Wuhan: a retrospective observational study. *Lancet Infect*
384 *Dis.* 2021; 21(5): 617-628.
- 385 11. Madewell ZJ, Yang Y, Longini IM Jr, et al. Factors associated with household
386 transmission of SARS-CoV-2: An updated systematic review and meta-analysis. *JAMA*
387 *Netw Open.* 2021; 4(8): e2122240.
- 388 12. Baker JM, Nakayama JY, O'Hegarty M, et al. SARS-CoV-2 B.1.1.529 (Omicron) variant
389 transmission within households - Four U.S. Jurisdictions, November 2021-February 2022.
390 *MMWR Morb Mortal Wkly Rep.* 2022; 71(9): 341-346.
- 391 13. Jørgensen SB, Nygård K, Kacelnik O, Telle K. Secondary Attack Rates for Omicron and
392 Delta Variants of SARS-CoV-2 in Norwegian Households. *JAMA* 2022; 327(16):
393 1610-1611.
- 394 14. Jalali N, Brustad HK, Frigessi A, et al. Increased household transmission and immune
395 escape of the SARS-CoV-2 Omicron variant compared to the Delta variant: evidence
396 from Norwegian contact tracing and vaccination data. *medRxiv* 22270437[Preprint].
397 February 18, 2022. [cited 2022 Jul 8]. Available from:
398 <https://doi.org/10.1101/2022.02.07.22270437>.
- 399 15. Lyngse FP, Mortensen LH, Denwood MJ, et al. SARS-CoV-2 Omicron VOC
400 Transmission in Danish Households. *medRxiv* 21268278[Preprint]. December 27, 2021.
401 [cited 2022 Jul 8]. Available from: <https://doi.org/10.1101/2021.12.27.21268278>.
- 402 16. Lyngse FP, Kirkeby CT, Denwood M, et al. Transmission of SARS-CoV-2 Omicron
403 VOC subvariants BA.1 and BA.2: Evidence from Danish Households. *medRxiv*
404 22270044[Preprint]. January 30, 2022. [cited 2022 Jul 8]. Available from:
405 <https://doi.org/10.1101/2022.01.28.22270044>.
- 406 17. World Health Organization. Household transmission investigation protocol for

- 407 coronavirus disease 2019 (COVID-19) Version: 2.2. 23 March 2020. Available at:
408 [https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/ea](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations)
409 [rly-investigations](https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/early-investigations). Accessed 1 June 2022.
- 410 18. National Health Commission of The People's Republic of China. Interim protocol of
411 diagnosis and treatment of 2019 novel coronavirus-associated pneumonia (Edition 9).
412 Available at: http://www.gov.cn/zhengce/zhengceku/2022-03/15/content_5679257.htm.
413 Accessed 15 Jun 2022.
- 414 19. World Health Organization. Living guidance for clinical management of COVID-19.
415 Available at: <https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2>.
416 Accessed 22 Jun 2022.
- 417 20. National Health Commission of The People's Republic of China. Protocol for Prevention
418 and Control of COVID-19 (Edition 8). Available at:
419 <http://www.nhc.gov.cn/jkj/s3577/202105/6f1e8ec6c4a540d99fafef52fc86d0f8.shtml>.
420 Accessed 22 Jun 2022.
- 421 21. Feikin DR, Abu-Raddad LJ, Andrews N, et al. Assessing vaccine effectiveness against
422 severe COVID-19 disease caused by omicron variant. Report from a meeting of the
423 World Health Organization. *Vaccine*. 2022; 40(26): 3516-3527.
- 424 22. Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of CoronaVac in children 3-5
425 years of age during the SARS-CoV-2 Omicron outbreak in Chile. *Nat Med*.
426 2022;28(7):1377-1380.
- 427 23. Florentino PTV, Alves FJO, Cerqueira-Silva T, et al. Vaccine effectiveness of CoronaVac
428 against COVID-19 among children in Brazil during the Omicron period. *Nat Commun*.
429 2022;13(1):4756.

- 430 24. Brandal LT, MacDonald E, Veneti L, et al. Outbreak caused by the SARS-CoV-2
431 Omicron variant in Norway, November to December 2021. *Euro Surveill.* 2021;
432 26(50):2101147.
- 433 25. Backer JA, Eggink D, Andeweg SP, et al. Shorter serial intervals in SARS-CoV-2 cases
434 with Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26
435 December 2021. *Euro Surveill.* 2022; 27(6):2200042.
- 436 26. Xin H, Wong J, Murphy C, et al. The Incubation Period Distribution of Coronavirus
437 Disease 2019: A Systematic Review and Meta-analysis. *Clin Infect Dis.* 2021; 73(12):
438 2344-2352.
- 439 27. Du Z, Liu C, Wang L, et al. Shorter serial intervals and incubation periods in
440 SARS-CoV-2 variants than the SARS-CoV-2 ancestral strain. *J Travel Med* 2022 Apr
441 20;taac052. doi: 10.1093/jtm/taac052.
- 442 28. Tanaka H, Ogata T, Shibata T, et al. Shorter Incubation Period among COVID-19 Cases
443 with the BA.1 Omicron Variant. *Int J Environ Res Public Health* 2022; 19(10):6330. doi:
444 10.3390/ijerph19106330.
- 445 29. Del Águila-Mejía J, Wallmann R, Calvo-Montes J, et al. Secondary Attack Rate,
446 Transmission and Incubation Periods, and Serial Interval of SARS-CoV-2 Omicron
447 Variant, Spain. *Emerg Infect Dis.* 2022; 28(6):1224-1228.
- 448 30. Song JS, Lee J, Kim M, et al. Serial Intervals and Household Transmission of
449 SARS-CoV-2 Omicron Variant, South Korea, 2021. *Emerg Infect Dis.*
450 2022;28(3):756-759.
- 451 31. Kremer C, Braeye T, Proesmans K, et al. Observed serial intervals of SARS-CoV-2 for
452 the Omicron and Delta variants in Belgium based on contact tracing data, 19 November
453 to 31 December 2021. *medRxiv* 22269756. [Preprint]. January 30, 2022. [cited 2022 Jul
454 8]. Available from: <https://doi.org/10.1101/2022.01.28.22269756>.

- 455 32. Kucharski AJ, Klepac P, Conlan AJK, et al. Effectiveness of isolation, testing, contact
456 tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different
457 settings: a mathematical modelling study. *Lancet Infect Dis.* 2020; 20(10): 1151- 1160.
- 458 33. Bi Q, Wu Y, Mei S, et al. Epidemiology and transmission of COVID-19 in 391 cases and
459 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet*
460 *Infect Dis.* 2020; 20(8): 911- 919.
- 461 34. Jing QL, Liu MJ, Zhang ZB, et al. Household secondary attack rate of COVID-19 and
462 associated determinants in Guangzhou, China: a retrospective cohort study. *Lancet Infect*
463 *Dis.* 2020; 20(10): 1141-1150.
- 464 35. Sun W, Ling F, Pan J, et al. Epidemiological characteristics of 2019 novel coronavirus
465 family clustering in Zhejiang province. *Zhonghua Yu Fang Yi Xue Za Zhi.* 2020; 54:
466 625-629 (in Chinese).
- 467 36. Wang Y, Tian H, Zhang L, et al. Reduction of secondary transmission of SARS-CoV-2 in
468 households by face mask use, disinfection and social distancing: a cohort study in Beijing,
469 China. *BMJ Glob Health* 2020; 5(5): e002794. doi: 10.1136/bmjgh-2020-002794.
- 470 37. Madewell ZJ, Yang Y, Longini IM Jr, et al. Household Secondary Attack Rates of
471 SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and
472 Meta-analysis. *JAMA Netw Open.* 2022; 5(4): e229317. doi:
473 10.1001/jamanetworkopen.2022.9317.
- 474 38. Iuliano AD, Brunkard JM, Boehmer TK, et al. Trends in Disease Severity and Health
475 Care Utilization During the Early Omicron Variant Period Compared with Previous
476 SARS-CoV-2 High Transmission Periods - United States, December 2020-January 2022.
477 *MMWR Morb Mortal Wkly Rep.* 2022; 71(4): 146-152.
- 478 39. Zhang L, Li Q, Liang Z, et al. The significant immune escape of pseudotyped
479 SARS-CoV-2 variant Omicron. *Emerg Microbes Infect.* 2022; 11(1): 1-5.

- 480 40. Higdon MM, Baidya A, Walter KK, et al. Duration of effectiveness of vaccination against
481 COVID-19 caused by the omicron variant. Lancet Infect Dis. 2022;22(8):1114-1116.
- 482 41. World Health Organization. Weekly epidemiological update on COVID-19 - 17 August
483 2022 (Edition 105).
484 [https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---17-august-2022)
485 [17-august-2022](https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---17-august-2022)

Fig. 1 Flow chart describing the procedure for screening study participants.




Table 1. Characteristics of the 236 primary cases and their 546 adult household contacts.

Characteristics	Primary cases (N=236)	Adult household contacts	
		Secondary cases (N=421)	Uninfected contacts (N=125)
Age group, years			
0-17	67 (28.39)	0 (0)	0 (0)
18+	169 (71.61)	421 (100)	125(100)
Sex			
Male	102 (43.22)	169 (40.14)	77 (61.6)
Female	134 (56.78)	252 (59.86)	48 (38.4)
Community exposure			
Yes	89 (37.71)	0 (0)	0 (0)
No	0 (0)	421 (100)	125(100)
Not determined	147 (62.29)	0 (0)	0 (0)
Vaccination status*			
Unvaccinated	89 (37.71)	98 (23.28)	13 (10.4)
Partial	7 (2.97)	21 (4.99)	4 (3.2)
Full	84 (35.59)	176 (41.81)	58 (46.4)
Booster	56 (23.73)	126 (29.93)	50 (40)
Symptom status			
Symptomatic	212 (89.83)	366 (86.94)	-
Asymptomatic	24 (10.17)	55 (13.06)	-

*Partial vaccination was defined as an individual receiving only one-dose inactivated vaccine. Full vaccination was defined as an individual receiving two doses of inactivated SARS-CoV-2 vaccines for at least 2 weeks. Booster vaccination was defined as a fully vaccinated individual receiving an additional dose of inactivated vaccine for at least 14 days.

Table 2. Infectivity of primary cases, measured by secondary infection attack rate (SAR_I) and secondary clinical attack rate (SAR_C), based on the analysis of 236 primary cases and their 546 adult household contacts*.

Characteristics of primary cases	No. of primary cases (N=236)	No. of adult household contacts (N=546)	No. of secondary cases (N=421)	Infectivity measured by SAR _I , % (95% CI)	P value	No. of secondary cases developing symptoms (N=366)	Infectivity measured by SAR _C , % (95% CI)	P value
Age group, years								
0-17	67	175	129	73.71 (67.19-80.24)	0.235	112	64 (56.89-71.11)	0.348
18+	169	371	292	78.71 (74.54-82.87)		254	68.46 (63.74-73.19)	
Sex								
Male	102	240	193	80.42 (75.4-85.44)	0.127	168	70 (64.2-75.8)	0.225
Female	134	306	228	74.51 (69.63-79.39)		198	64.71 (59.35-70.06)	
Vaccination status								
Unvaccinated	89	221	162	73.3 (67.47-79.14)	0.066	140	63.35 (57-69.7)	0.240
Partial [#]	7	12	7	-		6	-	
Full	84	187	146	78.07 (72.14-84)		131	70.05 (63.49-76.62)	
Booster	56	126	106	84.13 (77.75-90.51)		89	70.63 (62.68-78.59)	
Clinical severity								
Symptomatic	212	480	373	77.71 (73.98-81.43)	0.455	329	68.54 (64.39-72.7)	0.060
Asymptomatic	24	66	48	72.73 (61.98-83.47)		37	56.06 (44.09-68.03)	

* Households with co-primary cases or primary cases not determined were excluded from this analysis. We assessed the infectivity of primary cases among their adult household contacts to avoid potential bias due to the study design (detailed in Method Section). [#] The SAR_I and SAR_C among adult household contacts of a partially vaccinated primary case were not estimated due to the extremely small sample size (i.e., 12 household contacts corresponding to 7 primary cases)

Table 3. Susceptibility of adult household contacts, measured by secondary infection attack rate (SAR_I) and secondary clinical attack rate (SAR_C), based on the analysis of 546 adult household contacts from 236 households*.

Characteristics of adult household contacts	No. of adult household contacts	No. of secondary cases	Susceptibility measured by SAR _I , % (95% CI)	P value	No. of secondary cases developing symptoms	Susceptibility measured by SAR _C , % (95% CI)	P value
Overall	546	421	77.11 (73.58-80.63)	-	366	67.03 (63.09-70.98)	-
Sex							
Male	246	169	68.7 (62.9-74.49)	<0.001	144	58.54 (52.38-64.69)	<0.001
Female	300	252	84 (79.85-88.15)		222	74 (69.04-78.96)	
Vaccination status							
Unvaccinated	111	98	88.29 (82.31-94.27)	0.007	90	81.08 (73.79-88.37)	0.002
Partial	25	21	84 (69.63-98.37)		19	76 (59.26-92.74)	
Full	234	176	75.21 (69.68-80.75)		149	63.68 (57.51-69.84)	
Booster	176	126	71.59 (64.93-78.25)		108	61.36 (54.17-68.56)	

* Households with co-primary cases or primary cases not determined were excluded from this analysis. We assessed the susceptibility among adult household contacts to avoid potential bias due to the study design (detailed in Method Section).

Table 4. Effectiveness of inactivated vaccines (VE) against SARS-CoV-2 Omicron infection and symptomatic disease.

Vaccination status	VE against infection	VE against symptomatic infection
Unvaccinated	Ref	Ref
Partial	4.9 (-14.4, 20.8)	6.3 (-18.9, 26.1)
Full	14.8 (5.8, 22.9)	21.5 (10.4, 31.2)
Booster	18.9 (9.0, 27.7)	24.3 (12.3, 34.7)